Inflectis BioScience announced successful completion of Phase 1 clinical trial of IFB-088

Inflectis BioScience, one of the Remiges Ventures' portfolio companies announced today that it has completed its Phase 1 study for the firm's program IFB-008 successfully. IFB-088 is an oral small molecule targeting the stress-induced PPP1R15A/PP1c phosphatase complex. Results of this randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study (SAD/MAD) in 72 healthy volunteers demonstrated that administration of IFB-088 was safe and well tolerated. No serious adverse events, dose-limiting toxicities, or clinically significant abnormalities were observed. The pharmacokinetic parameters were consistent with data derived from extensive studies in animal models.